hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
![hVIVO plc](https://directorstalk.net/wp-content/uploads/2022/11/hVIVO-plc-300x300.jpg)
Breaking new ground in hMPV vaccine development
Amid rising concerns over human metapneumovirus (hMPV) infections, hVIVO’s innovative challenge model offers hope for accelerated vaccine development.